Scancell to focus on fundraising for Phase II trial of SCIB1
Clinical-stage pharma company Scancell Holdings says in 2017 it will focus on raising the funds necessary to commence a Phase II SCIB1 trial in combination with a checkpoint inhibitor.
FTSE AIM All-Share
738.36
16:54 04/10/24
Pharmaceuticals & Biotechnology
22,108.24
17:14 04/10/24
Scancell Holdings
13.25p
16:50 04/10/24
The company is developing two distinct immunotherapy platforms, each with broad applications and targeting multi-billion dollar markets.
ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors.
Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers.
"2017 will concentrate on raising the necessary funds to enable the commencement of a Phase II SCIB1 trial in combination with a checkpoint inhibitor," said Scancell in a statement.
At 10:33 GMT, shares in AIM-quoted Scancell were flat at 14.62p each.